VEGFR-2、PDGFR-β和c-MET在肝细胞癌中的表达及预后分析

临床肿瘤学杂志

VEGFR-2、PDGFR-β和c-MET在肝细胞癌中的表达及预后分析

储节胜1，徐建明2，张博3，葛飞娇2，刘烈军2，赵传华2，王岩2，林莉2，付亚丽2，汪俊3

100071 北京安徽医科大学解放军307临床学院消化肿瘤科

收稿日期:2012-03-07 修回日期:2012-04-21 出版日期:2012-07-31 发布日期:2012-07-31
通讯作者: 徐建明

Expressions of VEGFR-2，PDGFR-β and c-MET in hepatocellular carcinoma and their relationship with prognosis

CHU Jie-sheng，XU Jian-ming，ZHANG Bo，GE Fei-jiao，LIU Lie-jun，ZHAO Chuan-hua，WANG Yan，LIN Li，FU Ya-li，WANG Jun

Department of Digestive Oncology，307 Hospital of PLA，Anhui Medical University，Beijing 100071，China

Received:2012-03-07 Revised:2012-04-21 Online:2012-07-31 Published:2012-07-31

摘要/Abstract

摘要： 目的探讨血管内皮生长因子受体2（VEGFR-2）、血小板衍生生长因子受体β（PDGFR-β）和c-MET在肝细胞癌（HCC）中表达的临床意义及对预后的影响。方法应用免疫组织化学法检测93例HCC组织中VEGFR-2、PDGFR-β和c-MET的表达，分析其与临床病理特征和预后的关系。结果 VEGFR-2、PDGFR-β和c-MET在HCC组织中的高表达率分别为86.0％、19.4％和80.6％。VEGFR-2表达与性别、HBsAg状态、分化程度、肝硬化有关（P＜0.05），PDGFR-β表达与AFP、肿瘤数目、肝硬化有关（P＜0.05），c-MET表达与临床病理特征无关。Cox多因素回归分析显示，65例服用索拉非尼患者的无进展生存期（PFS）与年龄（P=0.047）有关，总生存期（OS）与HBsAg（P=0.037）、AFP（P=0.015）和肿瘤大小（P=0.003）有关；PDGFR-β表达水平与OS相关（P=0.046），c-MET与PFS相关（P=0.01）。结论 VEGFR-2在HCC合并肝硬化的患者中存在高表达，PDGFR-β高表达是HCC的预后不良指标，c-MET可能是HCC患者服用索拉非尼疗效的一个预测指标。

Abstract: Objective To explore the clinical significance and prognostic values of VEGFR-2，PDGFR-β and c-MET in patients with hepatocellular carcinoma（HCC）. Methods The expression of VEGFR-2，PDGFR-β and c-MET in 93 HCC patients was examined by immunohistochemistry（IHC）, and the correlation between clinical characteristics and progrosis was analyzed. Results The over-expression rates of VEGFR-2，PDGFR-β and c-MET in HCC were 86.0％，19.4％ and 80.6％，respectively. The expression of VEGFR-2 was related with sex，hepatitis B surface antigen（HBsAg） status，differentiation and hepatic cirrhosis（P＜0.05）. The expression of PDGFR-β was related with α-fetoprotein（AFP），number of tumor and hepatic cirrhosis（P＜0.05）. There was no significant relationship between the expression of c-MET and clinicopathological factors. Cox regression analysis showed that in 65 patients taking sorafenib，the progress free survival（PFS） was related to age（P=0.047），and the overall survival （OS） was related to HBsAg（P=0.037），AFP（P=0.015） and tumor size（P=0.003）. The expression of PDGFR-β was related with OS（P=0.046）. The expression of c-MET was related to PFS（P=0.01）. ConclusionThe expression level of VEGFR-2 is higher in HCC patients with hepatic cirrhosis. PDGFR-β is a biomarker for the poor prognosis in HCC patients. c-MET may be a prognostic factor to predict the therapeutic effect of HCC patients who have taken sorafenib.

储节胜1，徐建明2，张博3，葛飞娇2，刘烈军2，赵传华2，王岩2，林莉2，付亚丽2，汪俊3. VEGFR-2、PDGFR-β和c-MET在肝细胞癌中的表达及预后分析[J]. 临床肿瘤学杂志, 2012, 17(7): 609-.

CHU Jie-sheng，XU Jian-ming，ZHANG Bo，GE Fei-jiao，LIU Lie-jun，ZHAO Chuan-hua，WANG Yan，LIN Li，FU Ya-li，WANG Jun. Expressions of VEGFR-2，PDGFR-β and c-MET in hepatocellular carcinoma and their relationship with prognosis[J]. Chinese Clinical Oncology, 2012, 17(7): 609-.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed